{
  "id": 10308582,
  "title": "Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?",
  "url": "https://urgent.news/2026/09/27/bristol-myers-squibb-vs-novo-nordisk-which-healthcare-stock-is-a",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-27T22:00:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/better-buy/2026/09/27/bristol-myers-squibb-vs-novo-nordisk-healthcare-stock-better-buy-2026/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": null,
  "summary": "Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?",
        "url": "https://urgent.news/2026/09/27/bristol-myers-squibb-vs-novo-nordisk-which-healthcare-stock-is-a-10309687",
        "published": "2026-09-27T22:20:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}